Approval · Notice of Compliance 28087 · 2022
SKYRIZI: Notice of Compliance 28087
Issued May 4, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28087
- Date
- May 4, 2022
- Company
- AbbVie CorporationSaint-Laurent, Quebec, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of an alternate drug substance manufacturing site
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SKYRIZI | Not yet assigned | — |
Medicinal ingredients
- RISANKIZUMAB 90 MG per ML
- RISANKIZUMAB 150 MG per ML
- RISANKIZUMAB 150 MG per PEN